STOCKSSkin in the game: This dermatology market stock is a good M&A betBy Robert WassermanNov 4, 2016 12:43 PM EDT
STOCKSRebound may be in store for beaten-down shares of TherapeuticsMDBy Robert WassermanOct 12, 2016 2:33 PM EDT
STOCKSMomenta, coherus biosciences are both good options in the biosimilar spaceBy Robert WassermanOct 5, 2016 9:14 AM EDT
OPINIONChanges at the top for endo could benefit its smaller partnersBy Robert WassermanSep 26, 2016 9:03 AM EDT
STOCKSApplied genetic technologies is an attractive acquisition target for allergan or biogenBy Robert WassermanSep 20, 2016 9:05 AM EDT
STOCKS2 big companies and 1 small one to target in the pharma/biotech spaceBy Robert WassermanSep 8, 2016 9:07 AM EDT
STOCKSANI Pharmaceuticals' varied offerings, strategic acquisitions make it a good play for investorsBy Robert WassermanAug 30, 2016 9:29 AM EDT
STOCKSThis little-known orthopedic-device stock is delivering huge returnsBy Robert WassermanAug 29, 2016 12:38 PM EDT
INVESTINGChanging landscape for generic-drug makers creates opportunitiesBy Robert WassermanAug 8, 2016 2:25 PM EDT
OPINIONOpko Health's many acquisitions add up to varied product offerings and potential growthBy Robert WassermanAug 2, 2016 8:22 AM EDT
OPINION13 companies to watch from MIT's smart 50 list, including 4 buysBy Robert WassermanJul 21, 2016 7:48 AM EDT
OPINIONNeoGenomics deal with GE's Clarient 6 months later: boom or bust?By Robert WassermanJul 6, 2016 10:38 AM EDT
OPINIONOpko is a buying opportunity after FDA's approval of kidney drugBy Robert WassermanJun 30, 2016 5:15 PM EDT
